Cargando…
521. A phase II, double blind, placebo-controlled, randomized evaluation of the safety and efficacy of tafenoquine in patients with mild-moderate COVID-19 disease
BACKGROUND: Tafenoquine is an 8-aminoquinoline antimalarial approved by the US FDA for malaria prevention and is being evaluated in clinical trials for potential use in other disease areas. METHODS: The safety and efficacy of tafenoquine administered as a 200 mg dose once per day on days 1, 2, 3, an...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678769/ http://dx.doi.org/10.1093/ofid/ofad500.590 |